• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Pharma
    • Asia
    • Drug Delivery
    • Executives
    • Clinical Data
  • Vaccines
  • Special Reports
  • Trending
    • COVID-19
    • Cell & Gene Therapy
  • Podcasts
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Pharma
    • Asia
    • Drug Delivery
    • Executives
    • Clinical Data
  • Vaccines
  • Special Reports
  • Trending
    • COVID-19
    • Cell & Gene Therapy
  • Podcasts
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

Shire

Takeda HQ
Manufacturing

Takeda is calling it quits on Natpara's US commercial return

Takeda has elected to nix all manufacturing of its Natpara injection for hypoparathyroidism in the U.S. and abroad by the end of 2024.
Fraiser Kansteiner Oct 4, 2022 2:35pm
Novo Nordisk

Novo Nordisk's semaglutide misses the mark in NASH study

Jun 29, 2022 10:53am
Takeda CEO Christophe Weber

Takeda CEO Weber says pandemic, war could lower drug prices

Jun 2, 2022 7:42am
Iam17

Takeda taps doctor turned patient for rare disease campaign

Feb 4, 2022 8:24am
Asia Map

AstraZeneca, Takeda, Biogen, Samsung and more—Fierce Pharma Asia

Feb 4, 2022 6:26am
court decision

AbbVie dodges hedge fund lawsuit over failed $55B Shire pursuit

Sep 14, 2021 4:00pm
Home
  • Connect
    • The Team
    • Advertise
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Biotech
    • Fierce Healthcare
    • Fierce Pharma
  • Our Events
    • Life Sciences Events
©2023 Questex LLC All rights reserved.
Terms of use
Privacy Policy